All In Biotech

Drug Trial Radar · NCT05795140

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

A Multi-center, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Iptacopan in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Who Have Completed a Preceding Iptacopan Phase 3 Study in aHUS

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

May 8, 2024

Primary completion

Jul 16, 2032

Study completion Jul 27, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, single arm, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with aHUS.

Conditions

  • Atypical Hemolytic Uremic Syndrome

Interventions

  • Iptcaopan 200 mgDrug

    Open label, participant specific kits, hard gelatin capsules to be taken twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events and serious adverse eventsTime frame: Throughout the study duration, up to 4 years

Locations

10 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Rio de Janeiro, Brazil · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Active not recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Ostrava, Poruba, Czechia · Recruiting

  • Novartis Investigative Site

    Nagpur, Maharashtra, India · Active not recruiting

  • Novartis Investigative Site

    Pune, Maharashtra, India · Recruiting

  • Novartis Investigative Site

    Iruma-gun, Saitama, Japan · Recruiting

  • Novartis Investigative Site

    Ankara, Yenimahalle, Turkey (Türkiye) · Recruiting

  • Novartis Investigative Site

    Mersin, Yenisehir, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.